IgA nephropathy secondary prevention

Jump to navigation Jump to search


IgA nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating IgA nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

IgA nephropathy secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of IgA nephropathy secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on IgA nephropathy secondary prevention

CDC on IgA nephropathy secondary prevention

IgA nephropathy secondary prevention in the news

Blogs on IgA nephropathy secondary prevention

Directions to Hospitals Treating IgA nephropathy

Risk calculators and risk factors for IgA nephropathy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]

Overview

There are no established measures for the secondary prevention of IgA nephropathy.

Secondary Prevention

  • There are no established measures for the secondary prevention of IgA nephropathy.

References

Template:WH Template:WS